A Phase 3 interventional study of Prograf vs Envarsus XR vs Astagraf XL and Prograf vs Astagraf XL vs Envarsus XR in Renal Failure, sponsored by Veloxis Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-18.
Sponsored by Veloxis Pharmaceuticals · Phase 3, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing tacrolimus in Renal Insufficiency — none open to participants now, 1 under way, 1 of them phase 3. Tacrolimus · Renal Insufficiency.
Among the 17 studies testing tacrolimus in Renal Insufficiency, this one is the 15th largest by enrollment, is the only one that started in 2015, is one of 6 in phase 3, and was the 15th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.
Browse Renal Insufficiency studies →None of the 17 studies testing tacrolimus in Renal Insufficiency is open now. The open studies under Renal Insufficiency, anywhere →
Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 6 · Phase 4 6
First in 2003; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 40 across 1,060 interventional studies indexed under Renal Insufficiency.
Median enrollment 50 across the 17 interventional studies. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 17 have an industry lead sponsor. The 9 most frequent:
Veloxis Pharmaceuticals is the lead sponsor of 18 studies on the registry; 1 is open to participants now.
Veloxis Pharmaceuticals has 9 studies filed under Renal Insufficiency — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing tacrolimus in Renal Insufficiency, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare the pharmacokinetic parameters of three different formulations of tacrolimus.
Eligible patients will be treated with all three formulations in a pre-defined sequence.
The pharmacokinetic parameters T(max), C(max) and AUC(0-24) will be compared between the three formulations Envarsus XR once daily, Astagraf XL once daily and Prograf Twice daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prograft capsules Twice daily for 7 days, followed by Envarsus XR tablets once daily for 7 days followed by Astagraf XL capsules once daily for 7 days.
Drug: Prograf vs Envarsus XR vs Astagraf XL
Prograf capsules twice daily for 7 days followed by Astagraf XL capsules once daily for 7 days followed by Envarsus XR tablets once daily.
Drug: Prograf vs Astagraf XL vs Envarsus XR
prograf vs Envarsus XR vs Astagraf XL
Also known as: Tacrolimus
Prograf vs Astagraf XL vs Envarsus XR
Also known as: Tacrolimus
Evaluation of T(Max) for Envarsus XR, Astagraf XL and Prograf.
Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling times was used to calculate T(max). Nominal time points used were: Prograf sampling strategy (21 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, and 24. Envarsus XR sampling strategy (18 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, 24, and 27. Astagraf XL sampling strategy (17 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, and 24.
Time frame: 8 days
Evaluation of C(Max) for Envarsus XR, Astagraf XL and Prograf.
Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling times was used to calculate C(max). Nominal time points used were: Prograf sampling strategy (21 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, and 24. Envarsus XR sampling strategy (18 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, 24, and 27. Astagraf XL sampling strategy (17 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, and 24.
Time frame: 8 days
Evaluation of AUC(0-24) for Envarsus XR, Astagraf XL and Prograf.
Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling times was used to calculate AUC(0-24). Nominal time points used were: Prograf sampling strategy (21 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, and 24. Envarsus XR sampling strategy (18 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, 24, and 27. Astagraf XL sampling strategy (17 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, and 24.
Time frame: 8 days
32 patients were screened (enrolled) and 31 were randomized to treatment.
| Milestone | Envarsus XR | Astagraf XL | Prograf |
|---|---|---|---|
| Started | 0 | 0 | 31 |
| Completed | 0 | 0 | 31 |
| Not completed | 0 | 0 | 0 |
| Milestone | Envarsus XR | Astagraf XL | Prograf |
|---|---|---|---|
| Started | 16 | 15 | 0 |
| Completed | 16 | 15 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Envarsus XR | Astagraf XL | Prograf |
|---|---|---|---|
| Started | 15 | 16 | 0 |
| Completed | 15 | 16 | 0 |
| Not completed | 0 | 0 | 0 |
Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling times was used to calculate T(max). Nominal time points used were: Prograf sampling strategy (21 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, and 24. Envarsus XR sampling strategy (18 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, 24, and 27. Astagraf XL sampling strategy (17 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, and 24.
| hour | Envarsus XR | Astagraf XL | Prograf |
|---|---|---|---|
| Evaluation of T(Max) for Envarsus XR, Astagraf XL and Prograf. | 5.91 (1.45 to 13.95) | 1.93 (0.92 to 5.92) | 1.48 (0.93 to 19.97) |
Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling times was used to calculate C(max). Nominal time points used were: Prograf sampling strategy (21 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, and 24. Envarsus XR sampling strategy (18 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, 24, and 27. Astagraf XL sampling strategy (17 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, and 24.
| ng/mL | Envarsus XR | Astagraf XL | Prograf |
|---|---|---|---|
| Evaluation of C(Max) for Envarsus XR, Astagraf XL and Prograf. | 13.88 ± 5.331 | 13.17 ± 12.49 | 14.54 ± 13.60 |
Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling times was used to calculate AUC(0-24). Nominal time points used were: Prograf sampling strategy (21 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, and 24. Envarsus XR sampling strategy (18 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, 24, and 27. Astagraf XL sampling strategy (17 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, and 24.
| hr*ng/mL | Envarsus XR | Astagraf XL | Prograf |
|---|---|---|---|
| Evaluation of AUC(0-24) for Envarsus XR, Astagraf XL and Prograf. | 213.41 ± 83.095 | 165.02 ± 48.910 | 176.52 ± 50.799 |
Collected over Adverse events were collected from time of first dose of study drug and until last visit which was approximately 1 month.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Envarsus XR | — | 0/31 (0%) | 2/31 (6.5%) |
| Astagraf XR | — | 0/31 (0%) | 10/31 (32.3%) |
| Prograf | — | 0/31 (0%) | 3/31 (9.7%) |
| Event | Envarsus XR | Astagraf XR | Prograf |
|---|---|---|---|
| Oedema peripheralGeneral disorders | 0/31 | 3/31 | 0/31 |
| DiarrheaGastrointestinal disorders | 0/31 | 2/31 | 1/31 |
| VomitingGastrointestinal disorders | 0/31 | 2/31 | 0/31 |
| FatigueGeneral disorders | 2/31 | 0/31 | 0/31 |
| NasopharyngitisInfections and infestations | 0/31 | 2/31 | 0/31 |
| HeadacheNervous system disorders | 0/31 | 1/31 | 2/31 |
| Age, Categorical(Participants) | Prograf vs Envarsus XR vs Astagraf XL | Prograf vs Astagraf XL vs Envarsus XR | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 15 | 14 | 29 |
| >=65 years | 1 | 1 | 2 |
| Age, Continuous(years) | Prograf vs Envarsus XR vs Astagraf XL | Prograf vs Astagraf XL vs Envarsus XR | Total |
|---|---|---|---|
| Mean | 50.1 ± 11.00 | 46.3 ± 13.30 | 48.3 ± 12.11 |
| Sex: Female, Male(Participants) | Prograf vs Envarsus XR vs Astagraf XL | Prograf vs Astagraf XL vs Envarsus XR | Total |
|---|---|---|---|
| Female | 7 | 6 | 13 |
| Male | 9 | 9 | 18 |
| Region of Enrollment(participants) | Prograf vs Envarsus XR vs Astagraf XL | Prograf vs Astagraf XL vs Envarsus XR | Total |
|---|---|---|---|
| United States | 16 | 15 | 31 |
The record gives a start of Jan 2015, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tacrolimus
Veloxis Pharmaceuticals